Acute Intermittent Porphyria Market 规模与份额分析 - 成长趋势与预测 (2024 - 2031)
Acute Intermittent Porphyria Market is segmented By Treatment (RNA Interference-based Therapy, Givosiran, Symptomatic Treatment), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned.
Competitive overview of Acute Intermittent Porphyria Market
The major players operating in the Acute Intermittent Porphyria Market include Alnylam Pharmaceuticals, Recordati Rare Diseases, Mitsubishi Tanabe Pharma, Dicerna Pharmaceuticals, and Moderna.
Acute Intermittent Porphyria Market Leaders
- Alnylam Pharmaceuticals
- Recordati Rare Diseases
- Mitsubishi Tanabe Pharma
- Dicerna Pharmaceuticals
- Moderna
*Disclaimer: Major players are listed in no particular order.
Acute Intermittent Porphyria Market - Competitive Rivalry, 2023
Acute Intermittent Porphyria Market
Market Consolidated
(Dominated by major players)
(Dominated by major players)
Market Fragmented
(Highly competitive with lots of players.)
(Highly competitive with lots of players.)
*Source: Coherent Market Insights